Clearside’s Phase II Trial for DME Candidate Meets Primary Endpoint

June 8, 2018: By Jon Swedien

Clearside Biomedical’s Phase II study of suprachoroidal CLS-TA used with Eylea to treat diabetic macular edema (DME) met its primary endpoint, the company reported May 31.

CLS-TA is Clearside’s proprietary suspension of the corticosteroid triamcinolone acetonide formulated for administration to the back of the eye via the suprachoroidal space.

TYBEE—the multicenter, randomized, masked, controlled study—enrolled 71 patients who were naïve to DME treatment, and randomized them 1:1 to a combination arm or a control arm.

The combination arm received treatments of suprachoroidal CLS-TA together with intravitreal Eylea injections (two injections) at the beginning of the study and at the three-month mark.

Patients in the control arm received Eylea and a sham suprachoroidal procedure at the beginning of the study and at the one-, two, and three-month mark.

Patients in both arms were treated with Eylea at the four- and five-month marks if they needed it.

Clearside said the trial met its primary endpoint of mean improvement in best corrected visual acuity (BCVA) from baseline over six months, as measured using the Early Treatment of Diabetic Retinopathy Trial (ETDRS) scale.

Patients in the combination arm gained an average of 12.3 ETDRS letters compared with 13.5 ETDRS letters in the Eylea alone control arm (p = 0.664).

Clearside CEO Daniel White said the data suggests that suprachoroidal CLS-TA paired with an anti-VEGF agent could provide a longer response to treatment and substantially lower the treatment frequency.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Ivantis Gains US FDA Approval for Hydrus Microstent

US FDA Approves Sun Pharma’s CEQUA for Dry Eye

Regeneron Receives US FDA Approval for 12-Week Eylea Dosing

STAAR, Japan’s Shinjuku LASIK Clinic Sign Multiyear Agreement

Alcon Launches Finesse Sharkskin ILM Forceps

Imprimis’ Q2-2018 Revenues Increase 51 Percent to $10.4 Million

Bausch Health Revenues in Q2-2018 Drop 5 Percent

TearLab’s Q2-2018 Revenues Drop 8.5 Percent to $6.4 Million

DeepMind AI System Accurately Detects Eye Disease in OCT Scans at Moorfields

Study by MIT, Mass Eye and Ear Suggests Glaucoma is Autoimmune Disease

Study Indicates Insulin May Restore Vision in Glaucoma

CHOP Researchers Define Six ROP Indicators

Nicox Initiates Phase II Study of NCX 470 in Open-Angle Glaucoma, Ocular Hypertension

Eyenovia’s Microdose Latanoprost Delivers Drug with Precision, Lowers IOP in Proof-of-Concept Study

Rayner to Launch Sulcoflex Trifocal Toric IOL in September

CMS Allows Medicare Advantage Plans to Apply Step Therapy to Retinal Injections

Glaukos Reports Drug Collaboration with D. Western, Q2-2018 Net Sales Increase of 5 Percent

Allergan Will Co-develop Editas’ CRISPR Genome Editing Candidate for LCA10

Spark Reports Q2-2018 Net Sales of $4.3 Million for Luxturna

Aerie’s Rhopressa Posts $2.4 Million in Net Revenues in Q2-2018

Coming soon

2018 Ophthalmic Laser Report: A Global Market Analysis for 2017 to 2023 (Photocoagulation, Photodisruption, and SLT